CN108813620A - 一种改善睡眠的保健食品及其应用 - Google Patents
一种改善睡眠的保健食品及其应用 Download PDFInfo
- Publication number
- CN108813620A CN108813620A CN201811047832.3A CN201811047832A CN108813620A CN 108813620 A CN108813620 A CN 108813620A CN 201811047832 A CN201811047832 A CN 201811047832A CN 108813620 A CN108813620 A CN 108813620A
- Authority
- CN
- China
- Prior art keywords
- health food
- parts
- sleep
- improving sleep
- turmeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 39
- 230000007958 sleep Effects 0.000 claims abstract description 58
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 18
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 17
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 17
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 235000013976 turmeric Nutrition 0.000 claims abstract description 17
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 16
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 16
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 16
- 210000000582 semen Anatomy 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 4
- 235000008434 ginseng Nutrition 0.000 claims description 4
- 240000008866 Ziziphus nummularia Species 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 2
- 229940100688 oral solution Drugs 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 8
- 230000036541 health Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 231100000252 nontoxic Toxicity 0.000 abstract description 5
- 230000003000 nontoxic effect Effects 0.000 abstract description 5
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 231100000027 toxicology Toxicity 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 230000036578 sleeping time Effects 0.000 description 14
- 241000256856 Vespidae Species 0.000 description 13
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 9
- 230000028527 righting reflex Effects 0.000 description 8
- 230000004620 sleep latency Effects 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 229960000796 barbital sodium Drugs 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 7
- 206010003084 Areflexia Diseases 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000000147 hypnotic effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 102000018997 Growth Hormone Human genes 0.000 description 4
- 108010051696 Growth Hormone Proteins 0.000 description 4
- 208000010340 Sleep Deprivation Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000002673 Dioscorea communis Nutrition 0.000 description 1
- 241000544230 Dioscorea communis Species 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000035753 Periorbital contusion Diseases 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种改善睡眠的保健食品及其应用,该保健食品包括以下组分:炒酸枣仁650~960份、五味子60~360份、姜黄60~480份、西洋参105~240份。毒理学研究表明,本发明保健食品属于实际无毒级,具有很好的安全性;药效学试验表明,本发明保健食品具有显著的改善睡眠的作用;此配方可利用医学上认可的制剂的常规制备方法制备成不同剂型的改善睡眠的保健品,易于实现大生产。
Description
技术领域
本发明属于保健食品的技术领域,具体涉及一种改善睡眠的保健食品及其应用。
背景技术
睡眠是人类最重要和最基本的生理活动,足够的和高质量的睡眠是人类所必需的,但随着现代生活节奏的加快,人们的精神处在一种高度紧张的状态,焦虑症、抑郁症等不断发生,失眠的症状随之而产生,随着社会生活节奏的加快和社会竞争的激烈,失眠已成为多发病、常见病、其发病率逐年增高。其主要以经常不能获得正常睡眠为特征的一种病征,由于睡眠时间不足或质量差,从而产生疲倦和种种不适的感觉,注意力不集中,情绪不佳,头痛等,且经检查未发现其他器质病变的症状。睡眠不足存在以下的危害:(1)影响大脑的创造性思维:如长期睡眠不足会影响大脑的创造性思维和处理事物的能力;(2)影响青少年的生长发育:青少年的生长发育与生长激素的分泌有一定关系,而生长激素的分泌与睡眠密切相关,人在熟睡后有一个大的生长激素分泌高峰,随后又有几个小的分泌高峰,而在非睡眠状态,生长激素分泌减少;(3)影响皮肤的健康:充足的睡眠会使人的皮肤获得良好的新陈代谢,睡眠不足会引起皮肤毛细血管瘀滞,循环受阻,使得皮肤的细胞得不到充足的营养,从而加速皮肤的老化,使皮肤颜色显得晦暗而苍白,容易出现黑眼圈和皱纹;(4)导致疾病发生:经常睡眠不足或睡眠紊乱,会影响细胞的正常***,会使人心情忧虑焦急,免疫力降低,由此会导致种种疾病发生,如神经衰弱、感冒、胃肠疾病等甚至可能产生癌细胞的突变而导致癌症的发生;(5)引起肥胖:睡眠不足可以导致人体内消脂蛋白浓度的下降,同时能引起人体内食欲激素浓度的上升。
很多失眠多梦患者,长期得不到治愈或改善,形成对睡眠的一种恐惧感。因此,治愈心切,不顾后果的大量使用安眠类西药(如安定、氯硝安定、阿普***、褪黑素等)。虽然,治疗失眠的效果均比较显著,但长期使用,不仅副作用大,损伤肝肾脏腑,降低白细胞,而且会形成药物依赖性,一旦中断服用,失眠的症状就会反复复发,甚至更加严重。而中药治疗失眠已有千年的历史,相对化学药品而言,其具有安全无毒,作用缓和等优点。目前,用于改善睡眠的以中药材为主的保健食品,一般多是5种或以上组成的组方,配方较复杂,导致在生产过程中往往存在提取步骤较多,有效成分提取不完全等问题。
综上所述,本发明选用炒酸枣仁、姜黄、五味子、西洋参组方,其功为补肾养心,安神定志,改善睡眠。炒酸枣仁,养血安神,滋补营血,安神定志,为宁心安神之要药;五味子,滋肾,生津,具有收敛固涩,补肾宁心之功效,二者配伍取“苦酸制甜”之意;姜黄,解郁安神,其味辛散,辅枣仁通肝调营,所谓以辛补之。西洋参,补益心脾,交通心肾,补心养阴,达到安神,补而不燥的效果。依据中医理论,本品配方配伍合理。
迄今为止,未见其他文献及专利公开报道采用该组方改善人体的睡眠的保健食品。
发明内容
本发明的目的在于提供一种改善睡眠的保健食品,其配方中含有炒酸枣仁、五味子、姜黄、西洋参,遵循中医辨证施治的原则,配方各味药相辅相成,具有明显的改善睡眠的功效。
本发明采用如下技术方案:
本发明提供的一种改善睡眠的保健食品,由以下重量份配比的组分制备而成:炒酸枣仁650~960份、五味子60~360份、姜黄60~480份、西洋参105~240份。
所述保健食品由以下重量份配比的组分制备而成:炒酸枣仁700~840份、五味子120~300份、姜黄120~360份、西洋参115~180份。
优选地,所述保健食品由以下重量份配比的组分制备而成:所述保健食品由以下重量份配比的组分制备而成:炒酸枣仁720份、五味子240份、姜黄240份、西洋参120份。
本发明保健食品的制备方法如下:按配方比例称取炒酸枣仁、五味子、姜黄置提取罐中,70%乙醇煎煮提取2次,第一次加8倍量70%乙醇,第二次加6倍量70%乙醇,每次提取2小时,滤过,合并两次滤液,得提取液;提取液减压浓缩至60℃下相对密度为1.12~1.24,得稠浸膏;于真空度-0.06~-0.08Mpa、温度65℃~75℃的条件下真空干燥,得干膏,粉碎过100目筛,得干膏粉;将干膏粉、西洋参粉及食品辅料混合制成保健食品。
本发明以上述原料药组方制得的产品在制备用于改善睡眠的保健食品中的应用。
与现有技术相比,本发明具有如下优点:1)本发明以炒酸枣仁、姜黄、五味子、西洋参组方,其优势在于,非点对点的单纯阻断某种递质,而是多角度的调节身体机能,从而改善失眠症状;2)本发明采用纯中药制剂长期服用不会对人体产生副作用和精神依赖;3)本发明遵循“调治所病脏腑及其气血阴阳”的治疗原则,通过调整脏腑气血阴阳平衡,使脏腑恢复正常;4)经功能性试验证明,本发明保健食品属于实际无毒级,且具有改善睡眠的作用。
具体实施方式
为了使本领域的技术人员更好地理解本发明的技术方案,下面通过具体实施例对本发明作进一步的详细说明。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:制备改善睡眠的保健食品
配比(重量份):炒酸枣仁720g、五味子240g、姜黄240g、西洋参120g、微晶纤维素220g、聚维酮K30 34g、羧甲基淀粉钠20g、硬脂酸镁3g。
制备方法:按配方比例称取炒酸枣仁、五味子、姜黄置提取罐中,70%乙醇煎煮提取2次,第一次加8倍量70%乙醇,第二次加6倍量70%乙醇,每次提取2小时,滤过,合并两次滤液,得提取液;提取液减压浓缩至60℃下相对密度为1.12~1.24,得稠浸膏;于真空度-0.06~-0.08Mpa、温度65℃~75℃的条件下真空干燥,得干膏,粉碎过100目筛,得干膏粉;将干膏粉、西洋参粉、微晶纤维素、羧甲基淀粉钠,混合机混合20分钟,得混合粉;混合粉加入10%聚维酮K30水溶液润湿制软材,过20目筛制粒,湿颗粒用65℃~75℃干燥(干燥时间40~60min,至水分≤5%),干燥后过18目筛整粒,得干颗粒;取配方量的硬脂酸镁加至干颗粒中,混合均匀,混合时间为10min,得总混合颗粒,置压片机,压片。
实施例2:制备改善睡眠的保健食品
配比(重量份):炒酸枣仁605g、五味子360g、姜黄480g、西洋参105g。
制备方法:干膏粉的制备依据实施例1方法制成。将按实施例1制得的干膏粉与西洋参粉加入淀粉,与糊精适量混合均匀,制粒,干燥,装入胶囊即得。
实施例3:制备改善睡眠的保健食品
配比(重量份):炒酸枣仁960g、五味子120g、姜黄240g、西洋参180g。
制备方法:干膏粉的制备依据实施例1方法制成。将按实施例1制得的干膏粉与西洋参粉加入含甜菊糖苷的70%乙醇,混合均匀,再加入适量70%乙醇溶液制软材,14目筛制粒,得湿颗粒;湿颗粒65~75℃干燥,得干颗粒,过10目筛,得颗粒。
本发明功效性评价实验:
以实施例1制得的棕色片剂为样品进行改善睡眠功能的小鼠试验(检验单位:北京联合大学文理学院保健食品功能检测中心):
1.急性毒性试验
1.1 动物来源:选用北京维通利华实验动物技术有限公司[许可证号:SCXK(京)2012-0001]繁殖的SPF级昆明种小鼠,实验动物质量合格证:No.11400700170382。各实验组均给予维持饲料,维持饲料由北京科澳协力饲料有限公司[许可证号:SCXK(京)2014-0010]生产。
1.2 样品处理:本发明保健食品(以下简称样品),人体推荐用量约为4.5g/60kgBW。配制方法:充分研磨样品至粉末,称取粉末15.20g,加无菌水至40.0mL,充分混匀后作为受试样品。
1.3 剂量设计:选用18g~22g昆明种小鼠20只,雌雄各半,进行试验。试验期间动物自由摄食和饮水。以7.60g/kgBW的剂量,灌胃2次,间隔6h,灌胃剂量相当于15.20g/kgBW(相当于人体日摄入量的203倍),连续观察14d,观察并记录动物的一般状态、体重变化、中毒体征以及死亡情况等,确定最大耐受剂量(MTD)。
1.4 给样途径:灌胃,灌胃容量20mL/kgBW。
1.5 试验结果
小鼠经口急性毒性试验(MTD):给两种性别的小鼠灌胃2次受试样品,灌胃剂量为15.20g/kgBW,在观察的14d期间,动物状态正常,无中毒体征和死亡等异常情况。第15d将受试动物处死进行大体解剖检查,主要器官未见明显异常。受试样品对雌、雄小鼠的经口最大耐受剂量(MTD)均大于15g/kgBW。根据急性毒性分级标准,此受试样品属无毒级。结果见表1。
表1 急性毒性试验结果
2 药效学试验
2.1 动物来源:选用北京阜康生物科技股份有限公司[许可证号:SCXK(京)2014-0004]繁殖的BALB/C健康清洁级雄性小鼠,实验动物质量合格证:No.11401300048191。实验动物饲养于北京联合大学应用文理学院保健食品功能检测中心SPF级动物室,实验动物使用许可证号:SYXK(京)2012-0031。维持饲料由北京科澳协力饲料有限公司[许可证号:SCXK(京)2014-0010]生产。
2.2 样品处理:本发明保健食品(以下简称样品),人体推荐用量约为4.5g/60kgBW,相当于0.075g/kgBW/d。配制方法:分别称取样品5.62g、1.88g、0.95g,皆加无菌水至50.0mL,充分混匀后作为高、中、低剂量组。
2.3 剂量设计:选用18g~22gBALB/C健康清洁级雄性小鼠180只,共分为三批进行实验,每批随机分为4组,每组15只。实验一批进行直接睡眠实验和延长戊巴比妥钠诱导实验的小鼠睡眠时间实验;实验二批进行戊巴比妥钠阈下剂量催眠实验;实验三批进行巴比妥钠睡眠潜伏期实验。分别设人体推荐量的5、10、30倍,即每日0.38g/kgBW、0.75g/kgBW、2.25g/kgBW为低、中、高剂量组。经口每日一次给予,连续灌胃31d后测各项指标。同时设空白对照组(0g/kgBW),用无菌水代替受试样品,每日灌胃体积与各剂量组相同。各剂量组均给予维持饲料。
2.4 给样途径:灌胃,灌胃容量20mL/kgBW。
2.5 实验方法
2.5.1 直接睡眠试验:观察动物给予不同剂量受试样品,对照组给予同体积溶剂后,是否出现睡眠现象。睡眠以翻正反射消失为指标。当小鼠置于背卧位时,能立即翻正身位。如超过30~60秒不能翻正者,即认为翻正反射消失,进入睡眠。翻正反射恢复即为动物觉醒。翻正反射消失至恢复这段时间为动物睡眠时间,记录溶剂对照组与受试样品组入睡动物数及睡眠时间。睡眠时间为计量资料,采用方差分析。入睡动物数为计数资料,采用X2检验。比较对照组与实验组入睡动物数及睡眠时间之间的差异,若入睡动物数或睡眠时间增加有显著性,则实验结果阳性。
2.5.2 延长戊巴比妥钠睡眠时间试验:末次给予溶剂及不同剂量受试样品后,出现峰作用前15min,给各组动物腹腔注射36mg/kgBW戊巴比妥钠,注射量为0.2mL/20gBW。以小鼠翻正反射消失为睡眠指标,观察受试样品能否延长巴比妥钠诱导的睡眠时间。实验在夜间进行。睡眠时间为计量资料。比较实验组与对照组睡眠时间延长之间的差异,睡眠时间延长有显著性,则实验结果阳性。
2.5.3 戊巴比妥钠阈下剂量催眠试验:正式开始实验前先进行预实验,确定戊巴比妥钠阈下催眠剂量,即80%~90%小鼠翻正反射不消失的戊巴比妥钠最大阈下剂量。末次给予溶剂及不同剂量受试样品后,出现峰作用前15min,给各组动物腹腔注射26mg/kgBW戊巴比妥钠,注射量为0.2mL/20g/BW。以小鼠翻正反射消失达1min以上者为入睡标准,记录30min内入睡动物数。观察受试样品能否提高戊巴比妥钠阈下剂量入睡动物发生率。实验在夜间进行。入睡动物数为计数资料,采用X2检验。比较对照组与实验组入睡动物数之间的差异,入睡动物发生率增加有显著性,则实验结果阳性。
2.5.4 巴比妥钠睡眠潜伏期试验:末次给予溶剂及不同剂量受试样品15min后,给各组动物腹腔注射240mg/kgBW巴比妥钠,注射量为0.2mL/20gBW。以小鼠翻正反射消失为睡眠指标,观察受试样品对巴比妥钠睡眠潜伏期的影响。睡眠潜伏期为计量资料。比较实验组与对照组睡眠潜伏期之间的差异,睡眠潜伏期缩短有显著性,则实验结果阳性。
2.6 实验结果
2.6.1 样品对小鼠体重的影响,见表2、表3。
表2 小鼠的初始体重(±SD)
由表2可见,小鼠的初始体重在各剂量组与空白对照组(0g/kgBW)间比较,差异均无显著性(P>0.05)。即小鼠的初始体重在各组间较为均衡。
表3 样品对小鼠体重的影响(±SD)
由表3可见,经口给予小鼠不同剂量的样品31d后,小鼠体重在各剂量组与空白对照组(0g/kgBW)间比较,差异均无显著性(P>0.05)。即样品对小鼠体重无不良影响。
2.6.2 样品对小鼠直接睡眠实验的影响,见表4。
表4 样品对小鼠直接睡眠实验的影响(±SD)
由表4可见,对照组及各剂量组给予受试样品60min内,均未发现有直接睡眠现象。即样品无直接睡眠作用。
2.6.3 样品对戊巴比妥钠诱导小鼠睡眠时间的影响,见表5。
表5 样品对戊巴比妥钠诱导小鼠睡眠时间的影响(±SD)
*:与对照组(0 g/kgBW)比较有显著性差异。
由表5可见,经口给予小鼠不同剂量的受试样品31d后,与0 g/kgBW组比较,2.25g/kgBW组睡眠时间延长有显著性差异(P<0.01)。即样品在2.25g/kgBW组能延长戊巴比妥钠诱导的睡眠时间。
2.6.4 样品对戊巴比妥钠阈下剂量催眠小鼠入睡发生率的影响,见表6。
表6 样品对戊巴比妥钠阈下剂量催眠小鼠入睡发生率的影响(±SD)
由表6可见,经口给予小鼠不同剂量的受试样品31d后,各剂量组与0 g/kgBW组比较,入睡动物发生率均无显著性差异(P>0.05)。即样品对戊巴比妥钠阈下剂量催眠小鼠入睡动物发生率无影响。
2.6.5 样品对巴比妥钠诱导的小鼠睡眠潜伏期的影响,见表7。
表7 样品对巴比妥钠诱导的小鼠睡眠潜伏期的影响(±SD)
*:与对照组(0 g/kgBW)比较有显著性差异。
由表7可见,经口给予小鼠不同剂量的受试样品31d后,与0 g/kgBW组比较,2.25g/kgBW组睡眠潜伏期缩短有显著差异(P<0.05)。即样品在2.25g/kgBW组能缩短小鼠巴比妥钠诱导的睡眠潜伏期。
2.7 总结
根据《保健食品检验与评价技术规范》(2003版)改善睡眠保健食品的判定标准可知,本发明保健品改善睡眠功能动物实验结果阳性。
综上,在实验条件下本发明保健品无毒,且具有改善睡眠功能的作用。
Claims (6)
1.一种改善睡眠的保健食品,其特征在于,由以下重量份配比的组分制备而成:炒酸枣仁650~960份、五味子60~360份、姜黄60~480份、西洋参105~240份。
2.根据权利要求1所述的一种改善睡眠的保健食品,其特征在于,所述保健食品由以下重量份配比的组分制备而成:炒酸枣仁700~840份、五味子120~300份、姜黄120~360份、西洋参115~180份。
3.根据权利要求1所述的一种改善睡眠的保健食品,其特征在于,所述保健食品由以下重量份配比的组分制备而成:炒酸枣仁720份、五味子240份、姜黄240份、西洋参120份。
4.根据权利要求1所述的一种改善睡眠的保健食品,其特征在于,所述保健食品的制备方法如下:按配方比例称取炒酸枣仁、五味子、姜黄置提取罐中,70%乙醇煎煮提取2次,第一次加8倍量70%乙醇,第二次加6倍量70%乙醇,每次提取2小时,滤过,合并两次滤液,得提取液;提取液减压浓缩至60℃下相对密度为1.12~1.24,得稠浸膏;于真空度-0.06~-0.08Mpa、温度65℃~75℃的条件下真空干燥,得干膏,粉碎过100目筛,得干膏粉;将干膏粉、西洋参粉及食品辅料混合制成保健食品。
5.根据权利要求1所述的一种改善睡眠的保健食品,其特征在于,所述的保健食品为颗粒剂、片剂、胶囊剂、软胶囊剂、丸剂或口服液。
6.根据权利要求1-5中任一项所述的一种改善睡眠的保健食品在制备用于改善睡眠的保健食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811047832.3A CN108813620A (zh) | 2018-09-10 | 2018-09-10 | 一种改善睡眠的保健食品及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811047832.3A CN108813620A (zh) | 2018-09-10 | 2018-09-10 | 一种改善睡眠的保健食品及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108813620A true CN108813620A (zh) | 2018-11-16 |
Family
ID=64149198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811047832.3A Pending CN108813620A (zh) | 2018-09-10 | 2018-09-10 | 一种改善睡眠的保健食品及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108813620A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110368456A (zh) * | 2019-07-10 | 2019-10-25 | 胡铭 | 一种有助于改善睡眠的竹叶黄酮组合物 |
CN114796328A (zh) * | 2022-05-27 | 2022-07-29 | 华臻生物科技(深圳)有限公司 | 一种改善睡眠的组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101181054A (zh) * | 2006-11-14 | 2008-05-21 | 许洪之 | 一种改善睡眠的保健食品 |
CN105381059A (zh) * | 2015-11-28 | 2016-03-09 | 史克勇 | 可以改善睡眠障碍的药物 |
CN107137504A (zh) * | 2017-05-10 | 2017-09-08 | 南方医科大学 | 一种改善睡眠、增强免疫力的保健食品 |
-
2018
- 2018-09-10 CN CN201811047832.3A patent/CN108813620A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101181054A (zh) * | 2006-11-14 | 2008-05-21 | 许洪之 | 一种改善睡眠的保健食品 |
CN105381059A (zh) * | 2015-11-28 | 2016-03-09 | 史克勇 | 可以改善睡眠障碍的药物 |
CN107137504A (zh) * | 2017-05-10 | 2017-09-08 | 南方医科大学 | 一种改善睡眠、增强免疫力的保健食品 |
Non-Patent Citations (3)
Title |
---|
侯良绢等: "姜黄素对睡眠剥夺小鼠学习记忆力的影响 ", 《中国生物制品学杂志》 * |
李云等: "姜黄素对间歇性睡眠剥夺大鼠特定肠道菌的影响 ", 《中草药》 * |
王燕等: "HPLC-ELSD测定GSSM颗粒中酸枣仁皂苷A和人参皂苷Rb_1", 《中国实验方剂学杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110368456A (zh) * | 2019-07-10 | 2019-10-25 | 胡铭 | 一种有助于改善睡眠的竹叶黄酮组合物 |
CN114796328A (zh) * | 2022-05-27 | 2022-07-29 | 华臻生物科技(深圳)有限公司 | 一种改善睡眠的组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104547534B (zh) | 一种具有缓解视疲劳功效的中草药保健口服液 | |
CN104162094A (zh) | 一种治疗肥胖型***的中药组合物及其药物制剂 | |
CN108813620A (zh) | 一种改善睡眠的保健食品及其应用 | |
CN114028514B (zh) | 一种具有改善记忆作用枸杞子药食两用组合物及其制备方法与应用 | |
CN103223111A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
CN108785412B (zh) | 一种具有改善睡眠功能的组合物及其制备方法 | |
CN106420986A (zh) | 一种治疗感冒后咳嗽和咳嗽变异性哮喘的中药颗粒剂及制备方法和应用 | |
CN105230972A (zh) | 一种猪饲料及其制备方法 | |
CN107801990A (zh) | 一种辅助降血糖的保健食品及其制备方法 | |
CN101664533B (zh) | 一种治疗急慢性乳腺增生的中药及制备方法 | |
WO2017124826A1 (zh) | 用于治疗肝气郁结型经前期紧张综合症的中药药物 | |
CN110339277A (zh) | 妇科止带片及其制备方法 | |
CN111743968A (zh) | 一种植物组合物、其制备方法及应用 | |
CN105325714A (zh) | 一种牛配合饲料及其制备方法 | |
CN108785660A (zh) | 一种具有提高免疫力作用的牛骨胶原蛋白肽及其制备方法 | |
CN101757309B (zh) | 一种治疗崩漏的药物及其制备工艺 | |
CN101695522B (zh) | 一种治疗失眠的中药组合物 | |
CN110664903A (zh) | 一种具有降血脂功能的组合物及其制备方法和应用 | |
CN106177476A (zh) | 一种包含石斛和陈皮的降血糖保健组合物 | |
CN103845447B (zh) | 一种具有益气健脾养肝、养血养心安神功能的纯中药养生制剂 | |
CN104338017A (zh) | 具有改善睡眠作用的药物组合物及制法和应用 | |
CN104491416B (zh) | 一种用于治疗糖尿病的中药组合物 | |
CN113855754B (zh) | 一种祛瘀止血的中药组合物及其制备方法和应用 | |
CN108743791A (zh) | 一种镇静催眠的中药组合物 | |
CN105920142A (zh) | 一种治疗肝胆风热型原发性三叉神经痛的中药及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |